Results 31 to 40 of about 1,100,659 (258)

AIF1+CSF1R+ MSCs, induced by TNF‐α, act to generate an inflammatory microenvironment and promote hepatocarcinogenesis

Hepatology, EarlyView., 2022
Mesenchymal stem cells subset, educated by TNF‐α, are involved to generate inflammatory microenvironment and promote hepatocarcinogenesis Abstract Background and Aims Increasing evidence suggests that mesenchymal stem cells (MSCs) home to injured local tissues and the tumor microenvironment in the liver.
Chen Zong, Yan Meng, Fei Ye, Xue Yang, Rong Li, Jinghua Jiang, Qiudong Zhao, Lu Gao, Zhipeng Han, Lixin Wei   +9 more
wiley   +1 more source

Janus kinase 2 inhibition by pacritinib as potential therapeutic target for liver fibrosis

Hepatology, EarlyView., 2022
Diagram of the activation of the profibrotic and procontractile Janus kinase 2 (JAK2)/Ras homolog family member A/Rho‐kinase pathway and the inhibition of phosphorylated JAK2 by pacritinib to inhibit hepatic stellate cell activity. Abstract Background and Aims Janus kinase 2 (JAK2) signaling is increased in human and experimental liver fibrosis with ...
Sandra Torres, Cristina Ortiz, Nadine Bachtler, Wenyi Gu, Leon D. Grünewald, Nico Kraus, Robert Schierwagen, Christoph Hieber, Caroline Meier, Olaf Tyc, Maximilian Joseph Brol, Frank Erhard Uschner, Bart Nijmeijer, Christoph Welsch, Marie‐Luise Berres, Carmen Garcia‐Ruiz, Jose Carlos Fernandez‐Checa, Christian Trautwein, Thomas J. Vogl, Stefan Zeuzem, Jonel Trebicka, Sabine Klein   +21 more
wiley   +1 more source

Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival [PDF]

, 2012
Recent evidence suggests CML stem cells are insensitive to kinase inhibitors and responsible for minimal residual disease in treated patients. We investigated whether CML stem cells, in a transgenic mouse model of CML-like disease or derived from ...
Allan, Elaine K., Mueller-Tidow, Carsten, Nicolini, Franck E., Bhatia, Ravi, Brunton, Valerie G, Myssina, Svetlana, Hamilton, Ashley, Mysina, Svetlana, Müller-Tidow, Carsten, Koschmieder, Steffen, Allan, Elaine K, Helgason, G. Vignir, Helgason, G Vignir, Brunton, Valerie G., Schemionek, Mirle, Zhang, Bin, Holyoake, Tessa L., Holyoake, Tessa L, Nicolini, Franck E   +18 more
core   +1 more source

Characterization of VPS34-IN1, a selective inhibitor of Vps34, reveals that the phosphatidylinositol 3-phosphate-binding SGK3 protein kinase is a downstream target of class III phosphoinositide 3-kinase [PDF]

, 2014
The Vps34 (vacuolar protein sorting 34) class III PI3K (phosphoinositide 3-kinase) phosphorylates PtdIns (phosphatidylinositol) at endosomal membranes to generate PtdIns(3)P that regulates membrane trafficking processes via its ability to recruit a ...
Ward, Richard, Davies, Paul; id_orcid, Bago, Ruzica, Shpiro, Natalia, Cross, Darren, Sommer, Eeva, Malik, Nazma, Ganley, Ian G.; id_orcid, Munson, Michael J., Alessi, Dario R.; id_orcid, Prescott, Alan R.; id_orcid   +10 more
core   +1 more source

Janus Kinase Deregulation in Leukemia and Lymphoma [PDF]

, 2012
Genetic alterations affecting members of the Janus kinase (JAK) family have been discovered in a wide array of cancers and are particularly prominent in hematological malignancies.
Chen, Edwin, Staudt, L.M., Green, Anthony R., Staudt, Louis M., Chen, E., Green, A.R.   +5 more
core   +1 more source

The Role of Pharmacokinetics and Pharmacodynamics in Early Drug Development with reference to the Cyclin-dependent Kinase (Cdk) Inhibitor - Roscovitine. [PDF]

, 2011
Pharmacokinetics, pharmacodynamics and pharmacogenetics play an important role in drug discovery and contribute to treatment success. This is an essential issue in cancer treatment due to its high toxicity. During the last decade, cyclin-dependent kinase
Hassan, Moustapha, Sallam, Hatem, Hassan, Zuzana   +2 more
core   +4 more sources

Targeting sphingosine kinase 1 in carcinoma cells decreases proliferation and survival by compromising PKC activity and cytokinesis [PDF]

, 2012
Sphingosine kinases (SK) catalyze the phosphorylation of proapoptotic sphingosine to the prosurvival factor sphingosine 1-phosphate (S1P), thereby promoting oncogenic processes.
Zangemeister-Wittke, Uwe, Fabbro, Doriano, Doriano Fabbro, Huwiler Andrea, Zangemeister-Wittke Uwe, Huwiler, Andrea, Uwe Zangemeister-Wittke, Kotelevets Nataliya, Nataliya Kotelevets (156133), Kotelevets, Nataliya, Nataliya Kotelevets, Andrea Huwiler, Doriano Fabbro (156139), Andrea Huwiler (156145), Uwe Zangemeister-Wittke (156150), Fabbro Doriano   +15 more
core   +2 more sources

A case of Merkel cell carcinoma development under treatment with a Janus kinase inhibitor [PDF]

, 2017
JAAD Case Reports, 3(6), pp.498-500; 2017journal ...
Murayama, Naoya, Naoya Murayama, MD, Kuwatsuka, Yutaka, Koike, Yuta, Yutaka Kuwatsuka, Atsushi Utani, MD, PhD, Naoya Murayama, Atsushi Utani, Yuta Koike, Utani, Atsushi, Yuta Koike, MD, PhD, Yutaka Kuwatsuka, MD, PhD   +11 more
core   +1 more source

A case report of disseminated histoplasmosis and concurrent cryptococcal meningitis in a patient treated with ruxolitinib

BMC Infectious Diseases, 2019
Background Ruxolitinib is a highly potent janus kinase inhibitor that places its users at risk for various bacterial infections and viral reactivation.
Katya Prakash, Douglas Richman
doaj   +1 more source

Intracerebral bleeding after Janus-kinase inhibitor baricitinib for COVID-19

Brain Hemorrhages, 2021
Objectives: Intracerebral hemorrhage/bleeding (ICH) after an infection with SARS-CoV-2 (COVID-19) treated with the Janus-kinase inhibitor baricitinib has not been reported.
Josef Finsterer, Fulvio A. Scorza
doaj   +1 more source